Business
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL.","length":533,"tagName":"p"},{"type":"text","content":"Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented:"We are keen to support the submission of Volition's reimbursement dossier for its Nu.Q® Cancer assays so that we can introduce the test into routine, reimbursed clinical practice in France, through our extensive hospital network, for lung cancer management as soon as possible, hopefully later this year."","length":466,"tagName":"p"},{"type":"text","content":""We have worked closely with the Volition team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q® in the management of cancer patients. Our results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q® test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care." [1-3]","length":506,"tagName":"p"},{"type":"text","content":""Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring. This is a test we plan to use routinely."","length":236,"tagName":"p"},{"type":"text","content":"Frederic Wuilque, Vice President, Global Products, added:","length":57,"tagName":"p"},{"type":"text","content":""With the active support of HCL, we are working towards the submission of our reimbursement dossier before the end of this quarter under the framework of the "Innovative Procedures Outside the Nomenclature" (RIHN-référentiel des actes innovants hors nomenclature). Once the dossi...